By Fineline Cube 
Sino Biopharmaceutical Limited (HKG: 1177) and PT Tempo Scan Pacific Tbk (“Tempo Scan”) announced the official signing of a joint venture agreement to establish PT TEMPO CTTQ BIOPHARMACEUTICAL INDONESIA (TCBI) in Indonesia. Under the agreement, Sino Biopharmaceutical will hold a 51% stake in TCBI, while Tempo Scan will hold the remaining 49%.
Strategic Partnership Framework
| Item | Detail |
|---|---|
| Partners | Sino Biopharmaceutical Limited (HKG: 1177) / PT Tempo Scan Pacific Tbk |
| JV Entity | PT TEMPO CTTQ BIOPHARMACEUTICAL INDONESIA (TCBI) |
| Ownership Structure | Sino Biopharmaceutical: 51% / Tempo Scan: 49% |
| Geographic Focus | Indonesia |
| Primary Activities | Registration, clinical development, medical affairs, market access, and commercialization of innovative drugs and specialty pharmaceuticals |
| Future Considerations | Evaluation of local manufacturing opportunities |
Strategic Rationale & Capabilities Integration
- Sino Biopharmaceutical Contribution: Innovative drug R&D expertise, robust product pipeline, and international operations experience
- Tempo Scan Contribution: Local manufacturing capabilities, regulatory affairs expertise, market access networks, sales and marketing infrastructure, and nationwide distribution across Indonesia’s 17,000+ islands
- Synergy Model: Combines global innovation with local market penetration capabilities to address Indonesia’s underserved specialty pharmaceutical needs
- Market Entry Strategy: Leverages Tempo Scan’s established regulatory relationships and distribution channels to accelerate time-to-market for Sino Biopharmaceutical’s pipeline products
Indonesia Pharmaceutical Market Context
- Market Size: Indonesia represents Southeast Asia’s largest pharmaceutical market with estimated $9.2 billion in annual sales and 8-10% annual growth
- Population Access: Serves 275 million people with increasing demand for innovative therapies and specialty medicines
- Regulatory Environment: BPOM (Indonesia’s FDA equivalent) has streamlined approval pathways for innovative drugs through recent reforms
- Healthcare Infrastructure: Expanding universal healthcare coverage (JKN) creating increased demand for quality pharmaceuticals
- Local Manufacturing Incentives: Government policies favoring domestic production with tax incentives and import restrictions on certain drug categories
Strategic Impact & Growth Outlook
- Pipeline Acceleration: TCBI expected to advance 8-12 innovative drug candidates through Indonesian registration over the next 3 years
- Revenue Projection: Targeting $150-200 million in annual revenue by year 5 of operations
- Market Positioning: Positions Sino Biopharmaceutical as a leading Chinese innovator in Southeast Asia’s largest pharmaceutical market
- Competitive Advantage: First-mover advantage among Chinese biopharma companies establishing dedicated Indonesian commercial operations
- Long-term Vision: Potential platform for expansion into other ASEAN markets leveraging the Indonesia hub model
Forward‑Looking Statements
This brief contains forward-looking statements regarding the joint venture formation, strategic objectives, market opportunities, and financial projections. Actual results may differ due to risks including regulatory approvals, market acceptance, competitive dynamics, and geopolitical factors affecting Indonesia-China business relations.-Fineline Info & Tech